Tivanisiran

Unassigned

New Medicines

Ocular inflammation and pain-associated with moderate-to-severe dry eye syndrome

Information

New molecular entity
Sylentis
Sylentis

Development and Regulatory status

None
Phase III Clinical Trials
None

Category

A small interference RNA (siRNA) inhibitor of the TRPV1 receptor, a nociceptor that mediates pain and inflammation in corneal tissues, formulated as eye drops [1]
Ocular pain is a widespread disorder, and dry eye disease (DED) is a very common disorder affecting approximately 5-50% of the population. Although no uniform diagnostic criteria have been established, an estimated 300 million people worldwide are thought to suffer from DED. Dry eye prevalence is increasing due to current life style and aging of population [1].
Ocular inflammation and pain-associated with moderate-to-severe dry eye syndrome
Topical